$CNAT Income Statement

0
564

Conatus Pharmaceuticals Inc. (CNAT) -NasdaqGM In Watchlist

6.24 0.33(5.02%) Mar 20, 4:00PM EDT

Income Statement

Get Income Statement for:

View: Annual Data | Quarterly Data

All numbers in thousands

Period Ending

Dec 31, 2014

Sep 30, 2014

Jun 30, 2014

Mar 31, 2014

Total Revenue

–  

–  

–  

–  

Cost of Revenue

Gross Profit

–  

–  

–  

–  

Operating Expenses

Research Development

3,394

4,397

3,467

3,651

Selling General and Administrative

1,928

2,019

1,838

1,595

Non Recurring

Others

Total Operating Expenses

Operating Income or Loss

(5,321)

(6,416)

(5,305)

(5,246)

Income from Continuing Operations

Total Other Income/Expenses Net

2

(3)

19

20

Earnings Before Interest And Taxes

(5,319)

(6,420)

(5,286)

(5,226)

Interest Expense

18

18

18

18

Income Before Tax

(5,336)

(6,437)

(5,303)

(5,243)

Income Tax Expense

Minority Interest

Net Income From Continuing Ops

(5,336)

(6,437)

(5,303)

(5,243)

Non-recurring Events

Discontinued Operations

Extraordinary Items

Effect Of Accounting Changes

Other Items

Net Income

(5,336)

(6,437)

(5,303)

(5,243)

Preferred Stock And Other Adjustments

Net Income Applicable To Common Shares

(5,336)

(6,437)

(5,303)

(5,243)

LEAVE A REPLY

Please enter your comment!
Please enter your name here